Nexstim Plc Appoints Hanna Kotola as VP of Legal A
Post# of 301275
Company announcement, Helsinki, 24 April 2017 at 9:00 am
Nexstim Plc (NXTMH:HEX, NXTMS:STO) (" Nexstim " or " Company "), a medical technology company developing and marketing pioneering navigated non-invasive brain stimulation systems for both therapeutic (NBT® system) and diagnostic (NBS system) applications, announces the appointment of Hanna Kotola as Vice President, Legal Affairs effective from 1 June 2017. Mrs. Kotola will join the Nexstim Management Team and report to its CEO Martin Jamieson.
Hanna Kotola is an experienced international executive having previously held Group Corporate Counsel, Senior Legal Counsel and Legal Counsel roles at Polar Electro Oy, Digita Oy and Nokia Oyj.
Commenting on the appointment, Martin Jamieson, Chairman and CEO, Nexstim Plc stated: "I am very pleased to welcome Hanna Kotola to the team. Her broad legal experience will be invaluable as we continue to look to expand our market access via partnerships/distributor agreements. We are also looking at opportunities that will allow us to deliver increased NBT® system revenues in Europe. This will be based on leveraging the system's current CE marked indications, including most importantly stroke as well as depression and chronic pain."
NEXSTIM PLC Martin Jamieson, Chairman and CEO
Further information is available on the website www.nexstim.com or by telephone:
Nexstim +44 7715163942 Martin Jamieson, Chairman and CEO martin.jamieson@nexstim.com UB Securities Oy (Certified Adviser) +358 (0)9 2538 0246
Citigate Dewe Rogerson +44 (0)207 2821066 Katja Stout katja.stout@citigatedr.co.uk
About Nexstim Plc Nexstim is a medical technology company a medical technology company developing and marketing pioneering navigated non-invasive brain stimulation systems for both therapeutic (NBT® system) and diagnostic (NBS system) applications. Nexstim's NBS system is the only FDA cleared and CE marked system based on navigated Transcranial Magnetic Stimulation (nTMS) for the pre-surgical mapping of the speech and motor cortices of the brain.
Based on the same technology platform, the Company has developed the Navigated Brain Therapy (NBT®) which is CE marked for the treatment of stroke, major depression and chronic neuropathic pain. The NBT® system is currently in a supplemental Phase III study, E-FIT trial, which will recruit 60 patients. The trial is expected to complete in Q1 2018 allowing Nexstim to file for FDA clearance in April 2018. FDA clearance would allow Nexstim to start marketing and selling its NBT® system for stroke rehabilitation in the USA.
Nexstim shares are listed on the Nasdaq First North Finland and Nasdaq First North Sweden. For more information please visit www.nexstim.com
Attachments:
(0)
(0)